On August 28, MEDCAPTAIN (02041.HK), the Shenzhen-based medical device company, officially kicked off its global offering on the Hong Kong Stock Exchange, planning to issue 38.91 million H-shares at a fixed offer price of HK$15.42 per share, with trading expected to commence on September 7. The company, which operates across three business segments—life support, minimally invasive intervention, and in-vitro diagnostics—managed to swing back to profitability in 2025, only to record another loss in the first quarter of this year, adding an intriguing layer of uncertainty to its listing journey.
From Loss to Profit and Back Again
Financial data reveals that MEDCAPTAIN accumulated a net loss of approximately RMB 387 million from 2022 to 2024. In 2025, the company achieved revenue of RMB 1.619 billion, up 15.7% year-on-year, with a net profit of around RMB 48.89 million, successfully turning profitable. However, performance in the first quarter of 2026 has once again shown volatility. During the period, revenue reached RMB 422 million, a 19% increase, while gross margin improved to 54.3%. Yet, the company recorded a loss of approximately RMB 2.53 million to RMB 3.1 million, compared to a profit of RMB 5.02 million in the same period last year.
On an annual basis, MEDCAPTAIN's profitability is clearly improving—2025 full-year net profit approached RMB 50 million, with adjusted net profit (excluding share-based payments, intangible asset amortization, and other non-cash items) reaching RMB 129 million. Nevertheless, the return to a loss in Q1 highlights that the company's earnings stability still requires strengthening.
Three Core Business Lines and Global Footprint
Founded in 2011, MEDCAPTAIN is a globally positioned medical device enterprise with a comprehensive portfolio spanning life support, minimally invasive intervention, and in-vitro diagnostics. As of March 31, 2026, the company boasts over 60 life support products, 110 minimally invasive intervention products, and 150 in-vitro diagnostic products. Its offerings have been sold to more than 140 countries and regions worldwide, with domestic coverage exceeding 6,000 hospitals, including approximately 90% of top-tier Class A tertiary hospitals.
In China, the company ranks first in market share for infusion workstation equipment and holds a top-three position domestically for digestive system minimally invasive interventional consumables. Its brand portfolio includes MEDCAPTAIN, Penlon (a UK anesthesia brand), and Weidekang Medical.
Raising Nearly HK$500 Million Without Cornerstone Investors
Based on the offer price of HK$15.42 per share, and assuming no exercise of the over-allotment option, the company expects net proceeds of approximately HK$496 million from the global offering. The post-listing market capitalization is estimated at around HK$8.3 billion.
In terms of use of proceeds: approximately 35% will be allocated to ongoing and planned research and development to further enrich the product pipeline; 20% for developing manufacturing centers and expanding production capacity; 20% for enhancing sales and marketing capabilities; 10% for potential strategic investments and acquisitions globally; 5% for upgrading IT infrastructure and digital platforms; and 10% for working capital and other general corporate purposes.
Notably, this IPO has not brought in any cornerstone investors, nor has a stabilizing price operator been appointed. The joint sponsors are Morgan Stanley and Huatai International.
From 'Strategic Losses' to Earnings Reversal
MEDCAPTAIN experienced three consecutive years of losses from 2022 to 2024. The turnaround to profitability in 2025 was interpreted as the company crossing the threshold beyond its period of 'strategic losses.' However, the renewed loss in the first quarter of this year indicates that the profit foundation remains fragile. In 2025, approximately 83.1% of revenue came from distributors, reflecting a high level of channel dependence. Additionally, the company carries a relatively substantial amount of goodwill and intangible assets, meaning M&A integration and impairment risks also warrant close attention.
MEDCAPTAIN's listing path arrives at a delicate juncture where its profitability has shifted from 'turning positive' to 'wavering again.' For investors, the key question remains whether this medical device company, armed with a solid product line and global presence, can achieve sustainable profitability post-listing—a factor that will demand continuous monitoring.
Comments